Phaseline

Targets › ND4

ND4 (NADH-ubiquinone oxidoreductase chain 4): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 2, 1 Phase 1, 1 Phase 3; Neurology, Ophthalmology; next expected readout Feb 2028.

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor. Essential for the catalytic activity and assembly of complex I. (UniProt, P03905)

Open in Phaseline: the race on ND4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Wuhan Neurophth Biotechnology Limited CompanyrAAV2-ND4 (NR082)
Recombinant adeno-associated virus serotype 2 delivering wild-type ND4 gene for mitochondr
ND4Phase 3Leber Hereditary Optic Neuropathy (LHON); Leber's Hereditary Optic Neuropathy (LHON)Feb 2028
GenSight BiologicsGS010 (lenadogene nolparvovec, Lumevoq)
AAV5-delivered ND4 gene replacement therapy for LHON
ND4Phase 2Leber Hereditary Optic DiseaseMay 2028
Neurophth Therapeutics IncNR082 Injection
Gene therapy for mitochondrial ND4 mutation replacement
ND4Phase 1Leber Hereditary Optic Neuropathy (LHON)Dec 2029

Conditions

Leber Hereditary Optic Neuropathy (LHON) (2) Leber Hereditary Optic Disease (1) Leber's Hereditary Optic Neuropathy (LHON) (1)

Modalities

other (2), small molecule (1)

Companies

GenSight Biologics (1) Neurophth Therapeutics Inc (1) Wuhan Neurophth Biotechnology Limited Company (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.